Načítá se...
Site-specific PEGylation of an anti-CEA/CD3 bispecific antibody improves its antitumor efficacy
INTRODUCTION: Bispecific antibodies that engage immune cells to kill cancer cells are actively pursued in cancer immunotherapy. Different types of bispecific antibodies, including single-chain fragments, Fab fragments, nanobodies, and immunoglobulin Gs (IgGs), have been studied. However, the low mol...
Uloženo v:
| Vydáno v: | Int J Nanomedicine |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Dove Medical Press
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5985803/ https://ncbi.nlm.nih.gov/pubmed/29881272 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/IJN.S164542 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|